Contineum Therapeutics (CTNM) Other Accumulated Expenses (2023 - 2025)

Contineum Therapeutics' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $50000.0 for Q3 2025.

• On a quarterly basis, Other Accumulated Expenses fell 96.27% year-over-year to $50000.0 in Q3 2025; TTM through Sep 2025 was $50000.0, a 96.27% decrease from a year earlier, with the FY2024 full-year figure at $124000.0, up 22.77% from the prior year.
• Other Accumulated Expenses eased to $50000.0 in Q3 2025 per CTNM's latest filing, from $1.7 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.5 million in Q1 2025 and bottomed at $30000.0 in Q1 2024.
• The 3-year median for Other Accumulated Expenses is $548500.0 (2024), against an average of $847875.0.
• Biggest YoY gain for Other Accumulated Expenses was 8163.33% in 2025; the steepest drop was 96.27% in 2025.
• Year by year, Other Accumulated Expenses stood at $101000.0 in 2023, then rose by 22.77% to $124000.0 in 2024, then slumped by 59.68% to $50000.0 in 2025.
• Per Business Quant, the three latest CTNM Other Accumulated Expenses figures stand at $50000.0 (Q3 2025), $1.7 million (Q2 2025), and $2.5 million (Q1 2025).